Self-Management Intervention for Adult Cancer Survivors After Treatment: A Systematic Review and Meta-Analysis

Soo Hyun Kim, RN, PhD, OCN®, Kisook Kim, RN, PhD, and Deborah K. Mayer, RN, PhD, AOCN®, FAAN

Problem Identification: This study aims to evaluate the effects of self-management interventions (SMIs) for cancer survivors who completed primary treatment.

Literature Search: Using PubMed, EMBASE, CINAHL®, PsycINFO®, and Cochrane Central Register of Controlled Trials (CENTRAL), the authors conducted a systematic search of randomized, controlled trials published in English from database conception through June 2016.

Data Evaluation: The meta-analysis was conducted with Cochrane Review Manager, version 5.3, and R program, version 3.3.1.

Synthesis: 12 studies were systematically reviewed for self-management content, mode of delivery, session composition, and type of self-management skills used. Then, a meta-analysis of nine randomized, controlled trials involving 2,804 participants was conducted comparing SMIs with usual care, attention control, and a waitlist group. Qualitative synthesis showed that (a) the major study population was comprised of breast cancer survivors; (b) SMIs focused on medical/behavioral and emotional management; (c) the most common mode of delivery was web-based; and (d) the most frequently evaluated outcomes were depression, self-efficacy, and health-related quality of life (HRQOL). Quantitative results demonstrated a significant medium effect on HRQOL and a large effect on fatigue of borderline significance. The effects on anxiety, depression, and self-efficacy were not statistically significant.

Conclusions: SMIs had a significant medium effect on HRQOL for cancer survivors post-treatment, but the findings should be interpreted with caution because of substantial heterogeneity. In addition, the small number of studies limits conclusions.

Implications for Nursing: SMI as a nursing intervention for improving HRQOL of cancer survivors can be recommended, but more research should be undertaken to determine the most effective SMI format in terms of type, mode of delivery, and session composition.

Treatment completion does not signal the end of the cancer experience; many cancer survivors and their families continue to face problems associated with a complex chronic condition (Miller, 2008; Phillips & Currow, 2010). Long-term or late effects include fatigue (Kim et al., 2008; Pachman, Barton, Swetz, & Loprinzi, 2012), lymphedema (Paskett, Dean, Oliveri, & Harrop, 2012), anxiety and depression (Stanton, 2006), infertility (Ruddy & Partridge, 2012), sexual dysfunction (Bober & Varela, 2012), and cardiac complications (Lenihan & Cardinale, 2012), all of which negatively affect health-related quality of life (HRQOL) and increase medical costs (Hewitt, Greenfield, & Stovall, 2006). In addition, cancer survivors have elevated risks for additional malignancies and comorbid conditions, such as hypertension, diabetes, and osteoporosis (Rowland & Yancik, 2006; Schultz, Beck, Stava, & Vassilopoulou-Sellin, 2003; Wood et al., 2012). Therefore, long-term planning and preventive strategies are strongly recommended (Rowland & Yancik, 2006).
For cancer survivors, long-term planning requires an ongoing collaborative relationship between patients and healthcare providers rather than an acute, prescriptive relationship (McCorkle et al., 2011). These partnership relationships enable and empower patients to achieve their own care goals. Self-management may be a means of bridging the gap between survivors’ needs and the capacity of healthcare providers to meet those needs (Barlow, Wright, Sheasby, Turner, & Hainsworth, 2002).

Self-management in cancer survivorship has been defined as “awareness and active participation by the person in their recovery and rehabilitation to minimize the consequences of treatment and promote survival, health, and well-being” (Macmillan Cancer Support & NHS Improvement, 2010, p. 6). Self-management can empower patients with cancer, increase their confidence to manage problems associated with the disease and its treatment, and enhance HRQOL (Barlow, Bancroft, & Turner, 2005; Lorig, Sobel, Ritter, Laurent, & Hobbs, 2001).

Enthusiasm for self-management interventions (SMIs) for cancer survivors is growing as randomized, controlled trials (RCTs) provide evidence of its efficacy. SMIs significantly improve cancer knowledge (Gil et al., 2006; Mishel et al., 2005), cognitive reframing (Germo et al., 2013; Gil et al., 2006; Mishel et al., 2005), and self-efficacy (Lee et al., 2014; van den Berg et al., 2015; Yun et al., 2012); decrease psychological distress (e.g., anxiety, depression); and enhance HRQOL (Lee et al., 2014; Olesen et al., 2016; Yun et al., 2012). However, studies on the outcomes of self-management are not consistent, and some RCTs (Braamse et al., 2016; Foster et al., 2016; Owen et al., 2005) found no effects. Therefore, a need exists for a critical analysis of whether SMIs can improve physical or psychological outcomes among cancer survivors.

Four systematic reviews have contributed to the awareness of the importance of self-management in the area of cancer survivorship, but they did not focus on survivors who completed cancer treatment (Hammer et al., 2015; Kim & Park, 2015; McCorkle et al., 2011; Smith-Turchyn, Morgan, & Richardson, 2016). In the area of clinical practice and research, survivorship focuses on the health and life of a person with cancer post-treatment until the end of life (National Cancer Institute, 2017). A review focusing on people whose curative treatment has ended may contribute to the development of evidence-based SMIs for this population. In addition, two reviews evaluated the effects of only one mode of SMI delivery (i.e., web-based [Kim & Park, 2015] or group-based [Smith-Turchyn et al., 2016]), and the other two did not report quantitative synthesis (i.e., meta-analysis) (Hammer et al., 2015; McCorkle et al., 2011). Therefore, the current authors conducted a systematic review and meta-analysis of the effects of SMIs for cancer survivors who completed their primary treatment.

Methods

This systematic review and meta-analysis was guided by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement (Moher, Liberati, Tetzlaff, & Altman, 2009).

Eligibility Criteria

The authors selected only RCTs published in English from peer-reviewed journals. Eligibility criteria followed the PICO (Participants, Interventions, Controls, and Outcomes) framework (Liberati et al., 2009).

Participants were disease-free cancer survivors, aged 18 years or older, who completed curative primary cancer treatment (surgery, chemotherapy, radiation therapy, and/or adjuvant therapy). Participants diagnosed with cancer in childhood were excluded. SMI was defined as the systematic provision of education and supportive interventions with the purpose of promoting survivors’ skills in managing their condition, such as problem solving, decision making, resource use, forming partnerships, and taking action (Lorig & Holman, 2003). The authors included studies that applied at least one skill and compared them to the usual care group, attention control group, and waitlist group. Each eligible study included physical, psychological, cognitive, and/or behavioral outcomes measured with validated instruments.

Search Strategy

The authors conducted an extensive literature search in the electronic databases of PubMed, EMBASE, CINAHL®, PsycINFO®, and Cochrane Central Register of Controlled Trials (CENTRAL) from database conception through June 2016 using the following medical subject heading (MeSH) terms and keywords in the title or abstract: (“neoplasm” OR “cancer”) AND (“self-management” OR “self-care” OR “self-help” OR “self-administ*” OR “self-guided” OR “self-directed”) AND (“after care” OR “post treatment” OR “after treatment” OR “follow-up care” OR “survivorship”) AND (“randomized controlled trial” OR “randomised controlled trial” OR “randomiz*” OR “randomis*”). The authors then hand searched reference lists of the identified studies and relevant reviews.

Study Selection

Studies were selected following PRISMA guidelines (Moher et al., 2009). In the first step, one reviewer screened the titles and abstracts of all studies in a standardized manner and excluded those determined
to be irrelevant. In the second step, the authors retrieved full-text articles of all potentially relevant studies, and two authors independently screened each one using defined inclusion criteria. Disagreements were resolved by consensus.

**Data Extraction and Quality Assessment**

Two reviewers independently extracted data using a standardized data extraction sheet developed by the authors. Disagreements were resolved by discussion. Data extracted from the study included authors, year of publication, country of origin, sample characteristics, intervention details (contents of SMI, mode of delivery, sessions, self-management skills included), control conditions, study outcomes, and measurement time points.

The same two reviewers independently assessed the methodologic quality of the identified studies using the Cochrane Collaboration’s tool for assessing risk of bias (Higgins et al., 2011), which evaluates random sequence generation, allocation concealment, blinding of participants and staff, blinding of outcome assessment, incomplete outcome data, and selective reporting. Each item was rated as having a low, unclear, or high risk of bias. For these six items, blinding of assessors was not considered because all studies used self-reported questionnaires for outcome assessment. A pilot test was conducted of three studies before the authors independently assessed study quality. Disagreement was resolved by discussion.

**Statistical Analysis**

The authors performed a meta-analysis when an outcome was reported in three or more studies and the study provided enough data to allow the calculation of effect sizes. If the study had multiple measuring points postintervention, effect sizes were primarily calculated with the first post-test value. The authors also examined long-term effects of SMIs if available.

The authors estimated between-group standardized mean difference (SMD) with 95% confidence interval as the summary measure of effect and used means and standard deviations of outcomes to calculate the SMD (Cohen’s d). The authors considered a Cohen’s d of 0.8 to be large, 0.5 to be medium, and 0.2 to be small (Cohen, 1962). Chi-square statistics were used to assess heterogeneity. Chi-square values higher than 50% were considered to indicate substantial heterogeneity, and a random-effects model was applied to analyze the data (Higgins et al., 2011). The authors did not evaluate publication bias. According to the guidelines, tests for funnel plot asymmetry should be used only when a meta-analysis includes at least 10 studies; with fewer studies, the power of the tests is too low to rule out chance in the observed asymmetry (Higgins et al., 2011). The authors conducted the meta-analysis with Cochrane Review Manager, version 5.3, and R program, version 3.3.1, and considered p values less than 0.05 to be statistically significant. All statistical tests were two-sided.

**Results**

**Study Selection and Study Quality**

Figure 1 depicts the study selection flow diagram. Twelve articles met the eligibility criteria and were included in the systematic review. Three of them, however, did not include the necessary data for calculating effect size. Therefore, the meta-analysis was conducted with nine articles.

All trials except for one (Gil et al., 2006) reported an adequate method of random sequence generation, but six did not report an adequate method of allocation concealment. Given the nature of the psychosocial intervention, no trials applied study participant blinding, which inevitably causes performance bias. Ten studies reported the dropout and attrition rate, providing sufficiently complete data. Bias from selective reporting was observed in five trials that did not publish a protocol paper or report partial outcomes.

---

**FIGURE 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flow Diagram**

Records identified through database searching (n = 433)

Additional records identified through other sources (n = 6)

Duplicates removed (n = 79)

Records screened (n = 37)

Records excluded (n = 323)

Full-text articles assessed for eligibility (n = 37)

Studies included in qualitative synthesis (N = 12)

Studies included in quantitative synthesis (meta-analysis) (N = 9)

Full-text articles excluded (N = 25)

- Irrelevant population (n = 7)
- Conference abstract (n = 6)
- Irrelevant control group (n = 5)
- Protocol paper (n = 3)
- Irrelevant intervention (n = 2)
- Not a randomized, controlled trial (n = 1)
- Full text unavailable (n = 1)
Study Characteristics

Table 1 summarizes the characteristics of the 12 studies. Six were conducted in the United States, two in the Netherlands, two in South Korea, one in Denmark, and one in the United Kingdom. The sample sizes varied from 57–509, with a total of 2,804 participants. The most common cancer type was breast cancer (six studies); other cancer types included in the studies were three mixed, one hematologic, one gynecologic, and one prostate.

Intervention and Control Conditions

The mean duration of an SMI was 8.8 weeks (range = 4–16). Based on Lorig and Holman’s (2003) model, the authors categorized the contents of the intervention as medical/behavioral management, role management, or emotional management. The majority of SMIs (n = 7) dealt with emotional management, including distress management (Braamse et al., 2016; van den Berg et al., 2015), uncertainty management (Germino et al., 2013; Gil et al., 2006; Mishel et al., 2005), empowerment (Olesen et al., 2016), and coping (Owen et al., 2005). Four trials targeted medical/behavioral management, such as fatigue management (Foster et al., 2016; Yun et al., 2012), incontinence management (Zhang et al., 2015), or exercise and diet (Lee et al., 2014). Only one trial (Risendal et al., 2015) applied a multicomponent intervention, combining medical, role, and emotional management. No study used role management alone.

The most common mode of delivery was web-based, either alone (n = 5) or combined with a face-to-face encounter (n = 1). Four trials were administered face-to-face (two alone, one combined with the Internet, and one via telephone) (Olesen et al., 2016; Owen et al., 2005; Risendal et al., 2015; Zhang et al., 2015). Three were administered via telephone combined with audio recording (Germino et al., 2013; Gil et al., 2006; Mishel et al., 2005). All studies conducted via telephone used only telecounseling intervention, not smartphone mobile applications. The number of sessions varied according to the mode of delivery. In the web-based trials, the duration of the intervention was clearly indicated (range = 6–16 weeks), but time per session was not limited in most studies (Foster et al., 2016; Lee et al., 2014; Owen et al., 2005; van den Berg et al., 2015; Yun et al., 2012). Researchers asked participants to access the research website regularly (one to two times per week) (Braamse et al., 2016; Foster et al., 2016; Lee et al., 2014; van den Berg et al., 2015) in a self-guided (Owen et al., 2005) or tailored (Yun et al., 2012) manner. In trials using a telephone (Germino et al., 2013; Gil et al., 2006; Mishel et al., 2005; Zhang et al., 2015), the duration of the intervention ranged from 4–12 weeks, and time per session ranged from 20–45 minutes (X = 31.3 minutes).

The most frequently used self-management skill was problem solving (n = 10). Other skills included taking action (n = 9), resource use (n = 8), forming partnerships (n = 8), and decision making (n = 7). However, only two trials used the five skills together (Risendal et al., 2015; Yun et al., 2012).

The control groups were usual care (n = 6), attention control (n = 3), and waitlist (n = 3). The attention control group was provided with a leaflet (Foster et al., 2016) or a booklet (Lee et al., 2014) and telephone information (Germino et al., 2013).

Outcome Measures

All studies measured psychological outcomes with or without physical, social, or cognitive outcomes. Frequently measured outcomes were depression (n = 6), self-efficacy (n = 6), and HRQOL (n = 6), followed by fatigue (n = 5) and anxiety (n = 5). Fatigue as a physical outcome was measured using the Brief Fatigue Inventory (n = 3), the Piper Fatigue Scale (n = 1), or the Fatigue Severity Scale (n = 1). The authors of the examined studies commonly measured anxiety and depression with the Hospital Anxiety and Depression Scale (n = 5), and used the State–Trait Anxiety Inventory for anxiety and the Patient Health Questionnaire–9 for depression. Five of six studies of self-efficacy were for specific activities, such as exercise self-efficacy, diet self-efficacy, fatigue management self-efficacy, or breast cancer–specific self-efficacy. The most commonly used instrument for measuring HRQOL was the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 (n = 4). Others included the Functional Assessment of Cancer Therapy–Breast Cancer–Specific Module Questionnaire (n = 1), Functional Assessment of Cancer Therapy–General (n = 1), and Quality of Life–Cancer Survivors Instrument (n = 1).

Seven studies measured outcomes multiple times postintervention to examine long-term effects, with time points ranging from 12–80 weeks. Five studies selected 36 weeks postintervention as the long-term evaluation point.

Table 2 demonstrates the effect sizes of selected outcomes. Regarding physical outcomes, the authors observed a large effect on fatigue of borderline statistical significance (d = −1.17, p = 0.058, chi-square = 98%). Among psychological outcomes, the authors observed a significant medium effect on HRQOL (d = 0.55, p = 0.046, chi-square = 92%). The authors found no significant effects on anxiety (d = −0.2, p = 0.132, chi-square = 55%), depression (d = −0.07, p = 0.284, chi-square = 2%), or self-efficacy (d = 0.73, p = 0.117, chi-square = 55%). Among five study outcomes, the
### TABLE 1. Descriptive Summary of Included Qualitative Studies

<table>
<thead>
<tr>
<th>Study (Country)</th>
<th>Sample</th>
<th>Intervention</th>
<th>Outcomes Measured</th>
</tr>
</thead>
<tbody>
<tr>
<td>Braamse et al., 2016 (Netherlands)</td>
<td>Survivors treated with ASCT for hematologic cancer with experimental (n = 47) and control (n = 48) groups</td>
<td>Web-based emotional management program with 5 2-hour sessions during 6 weeks</td>
<td>Anxiety, depression, HRQOL, distress, problem solving, and self-efficacy were measured with HADS, EORTC QLQ-C30, PHQ-9, STAI-State, SPIS-R, and DGSS at baseline and 13, 30, and 42 weeks. Control condition was usual care.</td>
</tr>
<tr>
<td>Foster et al., 2016 (United Kingdom)</td>
<td>Mixed type of cancer survivors reporting moderate to severe fatigue with experimental (n = 85) and control (n = 78) groups</td>
<td>Web-based medical (fatigue) management program with weekly access for 6 weeks</td>
<td>Fatigue, self-efficacy, personal well-being, and depression were measured with PSEFSM, CS-SES, FACT-G, PWHI, PHQ-9, and BFI at baseline and at 6, 12, and 42 weeks. Control condition was attention control using a leaflet for coping with fatigue.</td>
</tr>
<tr>
<td>Germino et al., 2013 (United States)</td>
<td>Breast cancer survivors aged 50 years or younger with experimental (n = 167) and control (n = 146) groups</td>
<td>Telephone- and audio recording-based emotional management program with 4 20-minute sessions during 4 weeks</td>
<td>Cognitive reframing, problem solving, cancer knowledge, self-disclosure, source for and helpfulness of information, uncertainty, fears of recurrence, intrusive thoughts, symptoms, affect, personal growth, and self-efficacy were measured with SCS, CSKS, Disclosure Scale, SIC, MUIS-S, CAR-S, IES, ISI, MOS-SF, Piper Fatigue Scale, PNAS, GTUS, and Self-Efficacy for Breast Cancer at baseline and at 16–24 and 32–40 weeks. Control condition was attention control using 4 20-minute weekly telephone calls from graduate students.</td>
</tr>
<tr>
<td>Gil et al., 2006 (United States)</td>
<td>Breast cancer survivors with experimental (n = 229), and control (n = 254) groups</td>
<td>Telephone- and audio recording-based emotional management program with 4 30-minute sessions during 4 weeks</td>
<td>Uncertainty, cancer knowledge, social support satisfaction, patient–provider communication, cognitive reframing, coping, source for and helpfulness of information, negative mood state, and personal growth were measured with MUIS-S, CSKS, SSQ-SF, SCS, SCS, POMS-SF, and GTUS at baseline and at 40 and 80 weeks. Control condition was usual care.</td>
</tr>
<tr>
<td>Lee et al., 2014 (South Korea)</td>
<td>Breast cancer survivors with experimental (n = 29) and control (n = 28) groups</td>
<td>Web-based medical (fatigue) management program with 24 sessions during 12 weeks</td>
<td>Exercise and diet behaviors, diet quality, HRQOL, anxiety, depression, fatigue, stage of change, and self-efficacy were measured with EORTC QLQ-C30, HADS, and BFI at baseline and 12 weeks. Control condition was attention control using a booklet for exercise and diet.</td>
</tr>
<tr>
<td>Mishel et al., 2005 (United States)</td>
<td>Breast cancer survivors with experimental (n = 244) and control (n = 265) groups</td>
<td>Telephone- and audio recording-based emotional management program with 4 30-minute sessions during 4 weeks</td>
<td>Cognitive reframing, problem solving, cancer knowledge, social support satisfaction, patient–provider communication, coping, source for and helpfulness of information, and mood status were measured with CSKS, SSQ-SF, SCS, CSQ, and POMS-SF at baseline and 40 weeks. Control condition was usual care.</td>
</tr>
<tr>
<td>Olesen et al., 2016 (Denmark)</td>
<td>Gynecologic cancer survivors with experimental (n = 80) and control (n = 85) groups</td>
<td>Face-to-face emotional management program with 2–4 1-hour sessions during 12 weeks</td>
<td>HRQOL, impact of cancer, self-esteem, distress, anxiety, depression, autonomy support, and ability to monitor symptoms of recurrence were measured with QOL-CS, IOCSv2, Rosenberg Self-Esteem Scale, DT, HADS, and HCCQ at baseline and at 12 and 36 weeks. Control condition was usual care.</td>
</tr>
</tbody>
</table>

*Continued on the next page*
<table>
<thead>
<tr>
<th>Study (Country)</th>
<th>Sample</th>
<th>Intervention</th>
<th>Outcomes Measured</th>
</tr>
</thead>
<tbody>
<tr>
<td>Owen et al., 2005 (United States)</td>
<td>Breast cancer survivors with experimental (n = 32) and control (n = 30) groups</td>
<td>Face-to-face training and web-based emotional management program with a self-guided approach during 12 weeks SM skills: Problem solving, decision making, resource use, taking action</td>
<td>HRQOL, distress, physical well-being, expectations and satisfaction with website, and quality of participation were measured with FACT-B, IES, and MSAS at baseline and 12 weeks. Control condition was waitlist control.</td>
</tr>
<tr>
<td>Risendal et al., 2015 (United States)</td>
<td>Mixed type of cancer survivors with experimental (n = 169) and control (n = 89) groups</td>
<td>Face-to-face, group-based medical, role, and emotional management program with 6 2.5-hour sessions during 6 weeks SM skills: Problem solving, decision making, resource use, forming partnerships, taking action</td>
<td>Physical activity, health-seeking behaviors (communication with physician), self-efficacy, health status, energy, symptoms (pain, stress, and sleep problems), and depression were measured with PHQ-DS at baseline and 24 weeks. Control condition was waitlist control.</td>
</tr>
<tr>
<td>van den Berg et al., 2015 (Netherlands)</td>
<td>Breast cancer survivors with experimental (n = 70) and control (n = 80) groups</td>
<td>Web-based emotional management program with 16 sessions during 16 weeks SM skills: Problem solving, decision making, resource use, taking action</td>
<td>Distress, empowerment, fatigue, fear of recurrence, helplessness, self-efficacy, remoralization, personal control, acceptance, perceived benefit, HRQOL, fulfillment, reevaluation, new ways of living, and valuing life were measured with SCL-90, CEQ, HADS, DT, CIS, CWS, CAS, IQC, SES, RS12, EORTC QLQ-C30, and PAQ at baseline and at 16, 24, and 40 weeks. Control condition was waitlist control.</td>
</tr>
<tr>
<td>Yun et al., 2012 (South Korea)</td>
<td>Mixed type of cancer survivors reporting moderate to severe fatigue with experimental (n = 136) and control (n = 137) groups</td>
<td>Web-based medical (fatigue) management program with various sessions (range = 1–7) during 12 weeks SM skills: Problem solving, decision making, resource use, forming partnerships, taking action</td>
<td>Fatigue, physical activity, diet quality, energy conservation strategies, pain, sleep quality, anxiety and depression, and HRQOL were measured with BFI, FSS, EORTC QLQ-C30, ECSI, MNA, HADS, MOS-SS, and SQI at baseline and 12 weeks. Control condition was waitlist control.</td>
</tr>
<tr>
<td>Zhang et al., 2015 (United States)</td>
<td>Prostate cancer survivors with biofeedback plus support group (n = 91), biofeedback plus telephone contact (n = 94), and control (n = 91) groups</td>
<td>Face-to-face, group-based and telephone-based medical (incontinence) management program with 6 sessions during 12 weeks; sessions were 1–1.5 hours for the support group and 45 minutes for the telephone group. SM skills: Problem solving, forming partnerships, taking action</td>
<td>Daily urinary leakage and urinary function were measured at baseline and at 12 and 24 weeks. Control condition was usual care (biofeedback alone).</td>
</tr>
</tbody>
</table>

ASCT—autologous stem cell transplantation; BFI—Brief Fatigue Inventory; CARS—Concerns About Recurrence Scale; CAS—Cancer Acceptance Scale; CEQ—Cancer Empowerment Questionnaire; CIS—Checklist Individual Strength; CS-SES—Cancer Survivors’ Self-Efficacy Scale; CSKS—Cancer Survivor Knowledge Scale; CSQ—Coping Strategies Scale; CWS—Cancer Worry Scale; DGSS—Dutch General Self-Efficacy Scale; DT—Distress Thermometer; ECSI—Energy Conservation Strategies Inventory; EORTC QLQ-C30—European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30; FACT-B—Functional Assessment of Cancer Therapy—Breast Cancer; FACT-G—Functional Assessment of Cancer Therapy—General; FSS—Fatigue Severity Scale; GTUS—Growth Through Uncertainty Scale; HADS—Hospital Anxiety and Depression Scale; HCCQ—Health Care Climate Questionnaire; HRQOL—health-related quality of life; ICQ—Illness Cognition Questionnaire; IES—Impact of Events Scale; ILOCV2—Impact of Cancer, version 2; ISI—Insomnia Severity Scale; MOS—Medical Outcome Study—Sexual Functioning; MOS-SS—Medical Outcome Study—Sleep Scale; MSAS—Memorial Symptom Assessment Scale; MUIS—Michel Uncertainty in Illness Scale—Survivor version; PAQ—Positive Adjustment Questionnaire; PHQ-9—Patient Health Questionnaire—9; PHQ-DS—Personal Health Questionnaire—Depression Scale; PNAS—Positive Negative Affect Scale; POMS-SF—Profile of Mood States—Short Form; PSEFSM—Perceived Self-Efficacy for Fatigue Self-Management; PWI—Personal Well-Being Index; QOL-CS—Quality of Life—Cancer Survivors Instrument; RS12—Remoralization Scale—12 items; SCL-90—Symptom Checklist—90 items; SCS—Self-Control Schedule; SES—Self-Efficacy Scale; SIC—Source of Information Checklist; SM—self-management; SPSI-R—Social Problem Solving Inventory—Revised; SQI—Sleep Quality Index; SSQ-SF—Social Support Satisfaction—Short Form; STAI-State—State—Trait Anxiety Inventory—State version.
authors could calculate long-term effect sizes for depression (n = 2) and self-efficacy (n = 3) only. A significant small effect of SMI on self-efficacy was found (d = 0.27, p = 0.021, chi-square = 44.9%), but no significant long-term effect on depression was found (d = –0.2, p = 0.477, chi-square = 51%) (data not shown).

Discussion

The finding of a significant medium effect of SMI (d = 0.55) in improving the HRQOL of cancer survivors is consistent with Kim and Park’s (2015) finding for a web-based SMI. Because one of the goals of survivorship care is to improve HRQOL, the finding is encouraging. Another important finding was the large effect of SMI on fatigue (d = –1.17), but the role of chance cannot be ruled out (p = 0.058). Cancer-related fatigue is one of the most frequent problems cancer survivors report and can persist for years after treatment is completed (Kim et al., 2008; Leak Bryant, Walton, & Phillips, 2015). Given the growing body of literature, survivors who complain of cancer-related fatigue may benefit from nonpharmacologic intervention, such as exercise and cognitive behavioral therapy (Leak Bryant et al., 2015; Mitchell et al., 2014), but these programs are not accessible to many and often require substantial resources (Foster et al., 2016). In this respect, SMI for fatigue management is promising.

The null findings for the effect of SMI on anxiety and depression were unexpected. One possible explanation may relate to mode of delivery. The majority of studies that tested these outcomes (three of four for anxiety and four of six for depression) administered SMI using the Internet. Web-based programs can reach a large population in a cost-effective way (Foster et al., 2016), but their use does not guarantee delivery of the planned intervention dose because of the nature of the intervention itself. In addition, except in the trial by Braamse et al. (2016), anxiety and depression were not primary outcomes and were not screened at baseline. Many participants included in these trials showed minimal to mild levels of anxiety and depression, leading to null findings because of the bottom effect. Finally, only two trials (Risendal et al., 2015; Yun et al., 2012) used all five self-management skills (problem solving, decision making, resource use, forming partnerships, and taking action) suggested by Lorig and Holman’s (2003) model. Additional trials need to develop SMI using diverse skills to intensify efficacy. Of note, the authors found no significant self-efficacy effect at the first post-test time point (n = 5) but did at a delayed time point (n = 3), perhaps because of less heterogeneity (chi-square = 98% versus 45%). Because of the small number of studies, further evaluation is required.

Knowledge Translation

- Self-management intervention (SMI) for cancer survivors who completed their primary treatment may have beneficial effects on improving health-related quality of life and reducing fatigue.
- SMI may not be effective for other psychological outcomes, such as anxiety, depression, and self-efficacy.
- The meta-analytic evidence for the effects of SMI remains weak because studies are few and heterogeneous.

Qualitative synthesis revealed that program content focused only on medical/behavorial management (Foster et al., 2016; Lee et al., 2014; Yun et al., 2012; Zhang et al., 2015) and emotional management (Braamse et al., 2016; Germino et al., 2013; Gil et al., 2006; Mishel et al., 2005; Olesen et al., 2016; Owen et al., 2005; van den Berg et al., 2015). Healthcare professionals should be aware of the importance of role management, including in the family, at work, in communication, and in independent living. This is important in helping cancer survivors deal with their chronic condition in daily life.

The authors cannot draw firm conclusions about the effectiveness of single versus multiple content of SMI because the number of studies is small, but additional evaluations should fill in these details. In this study, only physical and psychological outcomes were reported. Three trials (Germino et al., 2013; Gil et al., 2006; Mishel et al., 2005) measured cognitive or social outcomes, such as cancer knowledge, cognitive reframing, and patient–provider communication, but the authors could not calculate the effect size for those because of insufficient data. Trials conducted with people with other chronic conditions have investigated SMI effects regarding cognitive or cost-effectiveness outcomes. Several reviews involving patients with type 2 diabetes or chronic obstructive pulmonary disease demonstrated that SMI had significant effects on improving disease knowledge and reducing hospital admissions and emergency department visits (Lian et al., 2017; Wang, Tan, Xiao, & Deng, 2017). Those outcomes warrant attention by clinicians and policy makers. Still, the majority of evidence comes from studies of breast cancer survivors, so additional trials are needed to expand the study population.

Limitations

The small number of studies (n = 9) included in the meta-analysis limits interpretation of the results. The authors could not perform moderator analysis (i.e., meta-regression), which could provide information about more effective SMI formats, and publication
bias could not be evaluated. In the analysis of long-term SMI effects, the authors reported results of only two outcomes (depression and self-efficacy) because of insufficient data regarding other outcomes. Given the importance of long-term care planning for cancer survivors after treatment, long-term trials are needed to identify the sustained effects of SMI. In addition, considerable heterogeneity was found among the included studies for all outcomes except for depression. Therefore, the results must be interpreted with caution. Another important limitation is the high risk of bias from nonblinding. It is impossible to blind participants when administering psychosocial interventions. Alternatively, researchers can use an attention control group and blind participants to the study hypothesis. Lastly, although the authors tried to retrieve all potentially eligible articles, some may have been missed.

### Implications for Nursing

Survivors are at risk not only for adverse treatment effects, but also for comorbid conditions (e.g.,

### TABLE 2. Effect Size of Self-Management Interventions

<table>
<thead>
<tr>
<th>Study</th>
<th>Experimental</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>X</td>
<td>SD</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------</td>
<td>---------</td>
</tr>
<tr>
<td>Fatigue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foster et al., 2016</td>
<td>83</td>
<td>74.1</td>
</tr>
<tr>
<td>Lee et al., 2014</td>
<td>29</td>
<td>13.5</td>
</tr>
<tr>
<td>van den Berg et al., 2015</td>
<td>70</td>
<td>28.6</td>
</tr>
<tr>
<td>Yun et al., 2012</td>
<td>136</td>
<td>2.78</td>
</tr>
<tr>
<td>Random effects model</td>
<td>318</td>
<td>-</td>
</tr>
<tr>
<td>Anxiety</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Braamse et al., 2016</td>
<td>47</td>
<td>3.53</td>
</tr>
<tr>
<td>Lee et al., 2014</td>
<td>29</td>
<td>6.6</td>
</tr>
<tr>
<td>Olesen et al., 2016</td>
<td>77</td>
<td>5.78</td>
</tr>
<tr>
<td>Yun et al., 2012</td>
<td>136</td>
<td>5.63</td>
</tr>
<tr>
<td>Random effects model</td>
<td>289</td>
<td>-</td>
</tr>
<tr>
<td>Self-efficacy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Braamse et al., 2016</td>
<td>47</td>
<td>3.17</td>
</tr>
<tr>
<td>Foster et al., 2016</td>
<td>83</td>
<td>8.41</td>
</tr>
<tr>
<td>Lee et al., 2014</td>
<td>29</td>
<td>7.3</td>
</tr>
<tr>
<td>Olesen et al., 2016</td>
<td>77</td>
<td>3.23</td>
</tr>
<tr>
<td>Risendal et al., 2015</td>
<td>169</td>
<td>6.9</td>
</tr>
<tr>
<td>Yun et al., 2012</td>
<td>136</td>
<td>5.26</td>
</tr>
<tr>
<td>Random effects model</td>
<td>541</td>
<td>-</td>
</tr>
<tr>
<td>Health-related quality of life</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Braamse et al., 2016</td>
<td>47</td>
<td>33.28</td>
</tr>
<tr>
<td>Foster et al., 2016</td>
<td>83</td>
<td>7.13</td>
</tr>
<tr>
<td>Germino et al., 2013</td>
<td>167</td>
<td>76.3</td>
</tr>
<tr>
<td>Risendal et al., 2015</td>
<td>169</td>
<td>72.4</td>
</tr>
<tr>
<td>van den Berg et al., 2015</td>
<td>70</td>
<td>21.13</td>
</tr>
<tr>
<td>Random effects model</td>
<td>536</td>
<td>-</td>
</tr>
</tbody>
</table>

CI—confidence interval; SMD—standardized mean difference

Note. Heterogeneity for each category was as follows: fatigue ($\chi^2 = 98\%$, $t^2 = 1.485$, $p < 0.01$), anxiety ($\chi^2 = 55\%$, $t^2 = 0.037$, $p < 0.09$), depression ($\chi^2 = 2\%$, $t^2 = 0.0006$, $p < 0.4$), self-efficacy ($\chi^2 = 98\%$, $t^2 = 1.085$, $p < 0.01$), and health-related quality of life ($\chi^2 = 92\%$, $t^2 = 0.4159$, $p < 0.01$).
another cancer, cardiovascular disease, diabetes, osteoporosis) (Mayer, Nasso, & Earp, 2017; Rowland & Yancik, 2006; Wood et al., 2012). This population is likely to be highly motivated to promote post-treatment health (Demark-Wahnefried, Pinto, & Gritz, 2006). Within this context, cancer survivors are recognized as having a chronic condition similar to diabetes or arthritis, and self-management is an essential component of care (Knobf et al., 2015). However, this meta-analysis could not conclusively demonstrate SMI effects because the only significant effect observed was in HRQOL; evidence for other outcomes remains unclear.

Oncology nurses are optimally positioned to deliver support for cancer survivor self-management. For more effective implementation of SMI, oncology nurses should consider the following points. First, intervention is needed to promote delivery of the planned intervention dose, particularly when it is web-based. Second, interventions need to be adapted to the survivor’s needs. Several studies that did not screen for specific needs failed to prove the effectiveness of the intervention. Third, interventions should be developed by using various self-management skills, such as problem solving, forming partnerships, and taking action. Fourth, long-term follow-up is needed to identify sustained SMI effects. Finally, future studies should investigate neglected issues, such as targeting a population other than breast cancer survivors; using face-to-face delivery; and measuring cognitive, social, or cost-effectiveness outcomes.

**Conclusion**

SMI had a significant medium effect on improving HRQOL among cancer survivors and a large effect of borderline significance on reducing fatigue. The authors found no significant effect on other psychological outcomes (i.e., anxiety, depression, and self-efficacy). Still, because of the small number of included studies, no definite conclusion can be drawn about practical issues about a more effective SMI format in terms of content, delivery mode, or session composition. More trials are needed because SMI could be an important part of the management of the growing number of cancer survivors.

**References**


